{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T11:21:55Z","timestamp":1774005715025,"version":"3.50.1"},"reference-count":186,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82271275"],"award-info":[{"award-number":["82271275"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Science and Technology Program Joint Program of Liaoning Province","award":["2023JH2\/101700204"],"award-info":[{"award-number":["2023JH2\/101700204"]}]},{"name":"Science and Technology Program Joint Program of Liaoning Province","award":["2023JH2\/101800017"],"award-info":[{"award-number":["2023JH2\/101800017"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s00415-025-13225-7","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T23:03:50Z","timestamp":1751411030000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Therapeutic strategies targeting complement in myasthenia gravis patients"],"prefix":"10.1007","volume":"272","author":[{"given":"Yinxiang","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianfei","family":"Nao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingjie","family":"Duan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zijian","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4902-8915","authenticated-orcid":false,"given":"Juan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,2]]},"reference":[{"key":"13225_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10112235","author":"L Dresser","year":"2021","unstructured":"Dresser L, Wlodarski R, Rezania K, Soliven B (2021) Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations. J Clin Med. https:\/\/doi.org\/10.3390\/jcm10112235","journal-title":"J Clin Med"},{"key":"13225_CR2","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41582-023-00916-w","volume":"20","author":"R Iorio","year":"2024","unstructured":"Iorio R (2024) Myasthenia gravis: the changing treatment landscape in the era of molecular therapies. Nat Rev Neurol 20:84\u201398. https:\/\/doi.org\/10.1038\/s41582-023-00916-w","journal-title":"Nat Rev Neurol"},{"key":"13225_CR3","doi-asserted-by":"publisher","first-page":"1404191","DOI":"10.3389\/fimmu.2024.1404191","volume":"15","author":"P Cavalcante","year":"2024","unstructured":"Cavalcante P, Mantegazza R, Antozzi C (2024) Targeting autoimmune mechanisms by precision medicine in Myasthenia Gravis. Front Immunol 15:1404191. https:\/\/doi.org\/10.3389\/fimmu.2024.1404191","journal-title":"Front Immunol"},{"key":"13225_CR4","doi-asserted-by":"publisher","DOI":"10.1172\/JCI179742","author":"HJ Kaminski","year":"2024","unstructured":"Kaminski HJ, Sikorski P, Coronel SI, Kusner LL (2024) Myasthenia gravis: the future is here. J Clin Invest. https:\/\/doi.org\/10.1172\/JCI179742","journal-title":"J Clin Invest"},{"key":"13225_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2022.102979","volume":"137","author":"SL Coss","year":"2023","unstructured":"Coss SL, Zhou D, Chua GT, Aziz RA, Hoffman RP, Wu YL, Ardoin SP, Atkinson JP, Yu CY (2023) The complement system and human autoimmune diseases. J Autoimmun 137:102979. https:\/\/doi.org\/10.1016\/j.jaut.2022.102979","journal-title":"J Autoimmun"},{"key":"13225_CR6","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1002\/mus.28227","volume":"70","author":"YF Huang","year":"2024","unstructured":"Huang YF, Sandholm K, Persson B, Nilsson B, Punga AR (2024) Visualization and characterization of complement activation in acetylcholine receptor antibody seropositive myasthenia gravis. Muscle Nerve 70:851\u2013861. https:\/\/doi.org\/10.1002\/mus.28227","journal-title":"Muscle Nerve"},{"key":"13225_CR7","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1080\/1744666X.2022.2082946","volume":"18","author":"MC Dalakas","year":"2022","unstructured":"Dalakas MC (2022) Role of complement, anti-complement therapeutics, and other targeted immunotherapies in myasthenia gravis. Expert Rev Clin Immunol 18:691\u2013701. https:\/\/doi.org\/10.1080\/1744666X.2022.2082946","journal-title":"Expert Rev Clin Immunol"},{"key":"13225_CR8","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.cll.2019.07.006","volume":"39","author":"M Ling","year":"2019","unstructured":"Ling M, Murali M (2019) Analysis of the complement system in the clinical immunology laboratory. Clin Lab Med 39:579\u2013590. https:\/\/doi.org\/10.1016\/j.cll.2019.07.006","journal-title":"Clin Lab Med"},{"key":"13225_CR9","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1111\/bph.15476","volume":"178","author":"E Rawish","year":"2021","unstructured":"Rawish E, Sauter M, Sauter R, Nording H, Langer HF (2021) Complement, inflammation and thrombosis. Br J Pharmacol 178:2892\u20132904. https:\/\/doi.org\/10.1111\/bph.15476","journal-title":"Br J Pharmacol"},{"key":"13225_CR10","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/S0140-6736(23)01524-6","volume":"403","author":"EE West","year":"2024","unstructured":"West EE, Woodruff T, Fremeaux-Bacchi V, Kemper C (2024) Complement in human disease: approved and up-and-coming therapeutics. Lancet 403:392\u2013405. https:\/\/doi.org\/10.1016\/S0140-6736(23)01524-6","journal-title":"Lancet"},{"key":"13225_CR11","doi-asserted-by":"publisher","first-page":"3571","DOI":"10.1182\/blood.2021012860","volume":"139","author":"E Gavriilaki","year":"2022","unstructured":"Gavriilaki E, de Latour RP, Risitano AM (2022) Advancing therapeutic complement inhibition in hematologic diseases: PNH and beyond. Blood 139:3571\u20133582. https:\/\/doi.org\/10.1182\/blood.2021012860","journal-title":"Blood"},{"key":"13225_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23158689","author":"R Zheng","year":"2022","unstructured":"Zheng R, Zhang Y, Zhang K, Yuan Y, Jia S, Liu J (2022) The complement system, aging, and aging-related diseases. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms23158689","journal-title":"Int J Mol Sci"},{"key":"13225_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242216515","author":"F Lasorsa","year":"2023","unstructured":"Lasorsa F, Rutigliano M, Milella M, Ferro M, Pandolfo SD, Crocetto F, Simone S, Gesualdo L, Battaglia M, Ditonno P, Lucarelli G (2023) Complement system and the kidney: its role in renal diseases, kidney transplantation and renal cell carcinoma. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms242216515","journal-title":"Int J Mol Sci"},{"key":"13225_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.902063","volume":"13","author":"Z Xu","year":"2022","unstructured":"Xu Z, Tao L, Su H (2022) The complement system in metabolic-associated kidney diseases. Front Immunol 13:902063. https:\/\/doi.org\/10.3389\/fimmu.2022.902063","journal-title":"Front Immunol"},{"key":"13225_CR15","doi-asserted-by":"publisher","unstructured":"DonadoCA, Theisen E, Zhang F, Nathan A, Fairfield ML, Rupani KV, Jones D, Johannes KP, RASLEN. Accelerating Medicines Partnership, Raychaudhuri S, Dwyer DF, Jonsson AH, Brenner MB (2025) Granzyme K activates the entire complement cascade. Nature. https:\/\/doi.org\/10.1038\/s41586-025-08713-9","DOI":"10.1038\/s41586-025-08713-9"},{"key":"13225_CR16","doi-asserted-by":"publisher","first-page":"917","DOI":"10.3389\/fimmu.2020.00917","volume":"11","author":"K Albazli","year":"2020","unstructured":"Albazli K, Kaminski HJ, Howard JF Jr (2020) Complement inhibitor therapy for myasthenia gravis. Front Immunol 11:917. https:\/\/doi.org\/10.3389\/fimmu.2020.00917","journal-title":"Front Immunol"},{"key":"13225_CR17","doi-asserted-by":"publisher","first-page":"317","DOI":"10.2147\/ITT.S261414","volume":"9","author":"R Mantegazza","year":"2020","unstructured":"Mantegazza R, Vanoli F, Frangiamore R, Cavalcante P (2020) Complement Inhibition for the Treatment of Myasthenia Gravis. Immunotargets Ther 9:317\u2013331. https:\/\/doi.org\/10.2147\/ITT.S261414","journal-title":"Immunotargets Ther"},{"key":"13225_CR18","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1080\/1744666X.2021.1936500","volume":"17","author":"A Evoli","year":"2021","unstructured":"Evoli A, Spagni G, Monte G, Damato V (2021) Heterogeneity in myasthenia gravis: considerations for disease management. Expert Rev Clin Immunol 17:761\u2013771. https:\/\/doi.org\/10.1080\/1744666X.2021.1936500","journal-title":"Expert Rev Clin Immunol"},{"key":"13225_CR19","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1186\/s12974-023-02946-z","volume":"20","author":"PY Liu","year":"2023","unstructured":"Liu PY, Li HQ, Dong MQ, Gu XY, Xu SY, Xia SN, Bao XY, Xu Y, Cao X (2023) Infiltrating myeloid cell-derived properdin markedly promotes microglia-mediated neuroinflammation after ischemic stroke. J Neuroinflammation 20:260. https:\/\/doi.org\/10.1186\/s12974-023-02946-z","journal-title":"J Neuroinflammation"},{"key":"13225_CR20","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1002\/mus.27973","volume":"68","author":"Y Ozawa","year":"2023","unstructured":"Ozawa Y, Uzawa A, Onishi Y, Yasuda M, Kojima Y, Kuwabara S (2023) Activation of the classical complement pathway in myasthenia gravis with acetylcholine receptor antibodies. Muscle Nerve 68:798\u2013804. https:\/\/doi.org\/10.1002\/mus.27973","journal-title":"Muscle Nerve"},{"key":"13225_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/cells13060508","author":"L Theissen","year":"2024","unstructured":"Theissen L, Schroeter CB, Huntemann N, Rauber S, Dobelmann V, Cengiz D, Herrmann A, Koch-Holsken K, Gerdes N, Hu H, Mourikis P, Polzin A, Kelm M, Hartung HP, Meuth SG, Nelke C, Ruck T (2024) Recombinant acetylcholine receptor immunization induces a robust model of experimental autoimmune myasthenia gravis in mice. Cells. https:\/\/doi.org\/10.3390\/cells13060508","journal-title":"Cells"},{"key":"13225_CR22","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/nyas.13522","volume":"1412","author":"JF Howard Jr","year":"2018","unstructured":"Howard JF Jr (2018) Myasthenia gravis: the role of complement at the neuromuscular junction. Ann N Y Acad Sci 1412:113\u2013128. https:\/\/doi.org\/10.1111\/nyas.13522","journal-title":"Ann N Y Acad Sci"},{"key":"13225_CR23","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/j.ajpath.2020.02.006","volume":"190","author":"CB Xie","year":"2020","unstructured":"Xie CB, Jane-Wit D, Pober JS (2020) Complement membrane attack complex: new roles, mechanisms of action, and therapeutic targets. Am J Pathol 190:1138\u20131150. https:\/\/doi.org\/10.1016\/j.ajpath.2020.02.006","journal-title":"Am J Pathol"},{"key":"13225_CR24","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.molimm.2022.08.018","volume":"151","author":"NSR Sanderson","year":"2022","unstructured":"Sanderson NSR (2022) Complement and myasthenia gravis. Mol Immunol 151:11\u201318. https:\/\/doi.org\/10.1016\/j.molimm.2022.08.018","journal-title":"Mol Immunol"},{"key":"13225_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2021.101085","volume":"297","author":"CA Warwick","year":"2021","unstructured":"Warwick CA, Keyes AL, Woodruff TM, Usachev YM (2021) The complement cascade in the regulation of neuroinflammation, nociceptive sensitization, and pain. J Biol Chem 297:101085. https:\/\/doi.org\/10.1016\/j.jbc.2021.101085","journal-title":"J Biol Chem"},{"key":"13225_CR26","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/s41581-023-00704-1","volume":"19","author":"EE West","year":"2023","unstructured":"West EE, Kemper C (2023) Complosome\u2014the intracellular complement system. Nat Rev Nephrol 19:426\u2013439. https:\/\/doi.org\/10.1038\/s41581-023-00704-1","journal-title":"Nat Rev Nephrol"},{"key":"13225_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/cells13060556","author":"E Dziadkowiak","year":"2024","unstructured":"Dziadkowiak E, Baczynska D, Waliszewska-Prosol M (2024) MuSK Myasthenia Gravis-Potential Pathomechanisms and Treatment Directed against Specific Targets. Cells. https:\/\/doi.org\/10.3390\/cells13060556","journal-title":"Cells"},{"key":"13225_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.787422","volume":"12","author":"M Maslinska","year":"2021","unstructured":"Maslinska M, Dmowska-Chalaba J, Jakubaszek M (2021) The role of IgG4 in autoimmunity and rheumatic diseases. Front Immunol 12:787422. https:\/\/doi.org\/10.3389\/fimmu.2021.787422","journal-title":"Front Immunol"},{"key":"13225_CR29","doi-asserted-by":"publisher","first-page":"1212757","DOI":"10.3389\/fimmu.2023.1212757","volume":"14","author":"AG Vakrakou","year":"2023","unstructured":"Vakrakou AG, Karachaliou E, Chroni E, Zouvelou V, Tzanetakos D, Salakou S, Papadopoulou M, Tzartos S, Voumvourakis K, Kilidireas C, Giannopoulos S, Tsivgoulis G, Tzartos J (2023) Immunotherapies in MuSK-positive Myasthenia Gravis; an IgG4 antibody-mediated disease. Front Immunol 14:1212757. https:\/\/doi.org\/10.3389\/fimmu.2023.1212757","journal-title":"Front Immunol"},{"key":"13225_CR30","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1159\/000330031","volume":"20","author":"E Tuzun","year":"2011","unstructured":"Tuzun E, Yilmaz V, Parman Y, Oflazer P, Deymeer F, Saruhan-Direskeneli G (2011) Increased complement consumption in MuSK-antibody-positive myasthenia gravis patients. Med Princ Pract 20:581\u2013583. https:\/\/doi.org\/10.1159\/000330031","journal-title":"Med Princ Pract"},{"key":"13225_CR31","doi-asserted-by":"publisher","first-page":"623","DOI":"10.11477\/mf.1416202652","volume":"76","author":"M Motomura","year":"2024","unstructured":"Motomura M, Kitanosono H, Yoshimura S, Shiraishi H (2024) Muscle-specific receptor tyrosine kinase antibody positive myasthenia gravis. Brain Nerve 76:623\u2013629. https:\/\/doi.org\/10.11477\/mf.1416202652","journal-title":"Brain Nerve"},{"key":"13225_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2023.148705","volume":"1825","author":"BH Chen","year":"2024","unstructured":"Chen BH, Lin ZY, Zeng XX, Jiang YH, Geng F (2024) LRP4-related signalling pathways and their regulatory role in neurological diseases. Brain Res 1825:148705. https:\/\/doi.org\/10.1016\/j.brainres.2023.148705","journal-title":"Brain Res"},{"key":"13225_CR33","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2300453120","volume":"120","author":"T Xie","year":"2023","unstructured":"Xie T, Xu G, Liu Y, Quade B, Lin W, Bai XC (2023) Structural insights into the assembly of the agrin\/LRP4\/MuSK signaling complex. Proc Natl Acad Sci USA 120:e2300453120. https:\/\/doi.org\/10.1073\/pnas.2300453120","journal-title":"Proc Natl Acad Sci USA"},{"key":"13225_CR34","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3389\/fimmu.2020.00212","volume":"11","author":"K Lazaridis","year":"2020","unstructured":"Lazaridis K, Tzartos SJ (2020) Autoantibody specificities in myasthenia gravis; implications for improved diagnostics and therapeutics. Front Immunol 11:212. https:\/\/doi.org\/10.3389\/fimmu.2020.00212","journal-title":"Front Immunol"},{"key":"13225_CR35","doi-asserted-by":"publisher","first-page":"e975","DOI":"10.1212\/WNL.0000000000012463","volume":"97","author":"Z Yu","year":"2021","unstructured":"Yu Z, Zhang M, Jing H, Chen P, Cao R, Pan J, Luo B, Yu Y, Quarles BM, Xiong W, Rivner MH, Mei L (2021) Characterization of LRP4\/Agrin antibodies from a patient with myasthenia gravis. Neurology 97:e975\u2013e987. https:\/\/doi.org\/10.1212\/WNL.0000000000012463","journal-title":"Neurology"},{"key":"13225_CR36","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200220","volume":"11","author":"O Chuquisana","year":"2024","unstructured":"Chuquisana O, Stascheit F, Keller CW, Pucic-Bakovic M, Patenaude AM, Lauc G, Tzartos S, Wiendl H, Willcox N, Meisel A, Lunemann JD (2024) Functional Signature of LRP4 Antibodies in Myasthenia Gravis. Neurol Neuroimmunol Neuroinflamm 11:e200220. https:\/\/doi.org\/10.1212\/NXI.0000000000200220","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"13225_CR37","doi-asserted-by":"publisher","first-page":"5190","DOI":"10.1172\/JCI66039","volume":"123","author":"C Shen","year":"2013","unstructured":"Shen C, Lu Y, Zhang B, Figueiredo D, Bean J, Jung J, Wu H, Barik A, Yin DM, Xiong WC, Mei L (2013) Antibodies against low-density lipoprotein receptor-related protein 4 induce myasthenia gravis. J Clin Invest 123:5190\u20135202. https:\/\/doi.org\/10.1172\/JCI66039","journal-title":"J Clin Invest"},{"key":"13225_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/cells8070671","author":"I Koneczny","year":"2019","unstructured":"Koneczny I, Herbst R (2019) Myasthenia gravis: pathogenic effects of autoantibodies on neuromuscular architecture. Cells. https:\/\/doi.org\/10.3390\/cells8070671","journal-title":"Cells"},{"key":"13225_CR39","doi-asserted-by":"publisher","first-page":"776","DOI":"10.3389\/fimmu.2020.00776","volume":"11","author":"ML Fichtner","year":"2020","unstructured":"Fichtner ML, Jiang R, Bourke A, Nowak RJ, O\u2019Connor KC (2020) Autoimmune pathology in myasthenia gravis disease subtypes is governed by divergent mechanisms of immunopathology. Front Immunol 11:776. https:\/\/doi.org\/10.3389\/fimmu.2020.00776","journal-title":"Front Immunol"},{"key":"13225_CR40","doi-asserted-by":"publisher","first-page":"290","DOI":"10.21037\/atm-19-363","volume":"11","author":"Y Li","year":"2023","unstructured":"Li Y, Peng Y, Yang H (2023) Serological diagnosis of myasthenia gravis and its clinical significance. Ann Transl Med 11:290. https:\/\/doi.org\/10.21037\/atm-19-363","journal-title":"Ann Transl Med"},{"key":"13225_CR41","doi-asserted-by":"publisher","unstructured":"EvoliA, Palace J, Spagni G, Cheli M, Ruiter A, Verschuuren J, Maggi L, Esg. th (2024) 275th ENMC international workshop: Seronegative myasthenia gravis: An update paradigm for diagnosis and management, 9\u201311 February 2024, Hoofddorp, the Netherlands, Neuromuscul Disord 44:104468. https:\/\/doi.org\/10.1016\/j.nmd.2024.104468","DOI":"10.1016\/j.nmd.2024.104468"},{"key":"13225_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci13091286","author":"C Vinciguerra","year":"2023","unstructured":"Vinciguerra C, Bevilacqua L, Lupica A, Ginanneschi F, Piscosquito G, Rini N, Rossi A, Barone P, Brighina F, Di Stefano V (2023) Diagnosis and management of seronegative myasthenia gravis: lights and shadows. Brain Sci. https:\/\/doi.org\/10.3390\/brainsci13091286","journal-title":"Brain Sci"},{"key":"13225_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.596981","volume":"11","author":"K Lazaridis","year":"2020","unstructured":"Lazaridis K, Tzartos SJ (2020) Myasthenia gravis: autoantibody specificities and their role in MG management. Front Neurol 11:596981. https:\/\/doi.org\/10.3389\/fneur.2020.596981","journal-title":"Front Neurol"},{"key":"13225_CR44","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/s0165-5728(00)00394-5","volume":"111","author":"F Romi","year":"2000","unstructured":"Romi F, Skeie GO, Vedeler C, Aarli JA, Zorzato F, Gilhus NE (2000) Complement activation by titin and ryanodine receptor autoantibodies in myasthenia gravis. A study of IgG subclasses and clinical correlations. J Neuroimmunol 111:169\u2013176. https:\/\/doi.org\/10.1016\/s0165-5728(00)00394-5","journal-title":"J Neuroimmunol"},{"key":"13225_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.596621","volume":"11","author":"H Frykman","year":"2020","unstructured":"Frykman H, Kumar P, Oger J (2020) Immunopathology of autoimmune myasthenia gravis: implications for improved testing algorithms and treatment strategies. Front Neurol 11:596621. https:\/\/doi.org\/10.3389\/fneur.2020.596621","journal-title":"Front Neurol"},{"key":"13225_CR46","doi-asserted-by":"publisher","first-page":"1555075","DOI":"10.3389\/fimmu.2025.1555075","volume":"16","author":"S Lehnerer","year":"2025","unstructured":"Lehnerer S, Stegherr R, Grittner U, Stein M, Gerischer L, Stascheit F, Herdick M, Doksani P, Meisel A, Hoffmann S (2025) The burden of disease in seronegative myasthenia gravis: a patient-centered perspective. Front Immunol 16:1555075. https:\/\/doi.org\/10.3389\/fimmu.2025.1555075","journal-title":"Front Immunol"},{"key":"13225_CR47","doi-asserted-by":"publisher","first-page":"707","DOI":"10.3389\/fimmu.2020.00707","volume":"11","author":"LS Borges","year":"2020","unstructured":"Borges LS, Richman DP (2020) Muscle-specific kinase myasthenia gravis. Front Immunol 11:707. https:\/\/doi.org\/10.3389\/fimmu.2020.00707","journal-title":"Front Immunol"},{"key":"13225_CR48","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-025-08096-9","author":"C Antozzi","year":"2025","unstructured":"Antozzi C, Frangiamore R, Rinaldi E, Vanoli F, Andreetta F, Grigoli EG, Ciusani E, Bonanno S, Maggi L, Mantegazza R (2025) Efgartigimod improves non-AChR generalized Myasthenia Gravis: a real world experience. Neurol Sci. https:\/\/doi.org\/10.1007\/s10072-025-08096-9","journal-title":"Neurol Sci"},{"key":"13225_CR49","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16306","volume":"31","author":"B Sorrenti","year":"2024","unstructured":"Sorrenti B, Laurini C, Bosco L, Strano CMM, Scarlato M, Gastaldi M, Filippi M, Previtali SC, Falzone YM (2024) Overcoming therapeutic challenges: successful management of a supposedly triple seronegative, refractory generalized myasthenia gravis patient with efgartigimod. Eur J Neurol 31:e16306. https:\/\/doi.org\/10.1111\/ene.16306","journal-title":"Eur J Neurol"},{"key":"13225_CR50","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s40265-022-01678-3","volume":"82","author":"YA Heo","year":"2022","unstructured":"Heo YA (2022) Efgartigimod: first approval. Drugs 82:341\u2013348. https:\/\/doi.org\/10.1007\/s40265-022-01678-3","journal-title":"Drugs"},{"key":"13225_CR51","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1007\/s40265-023-01933-1","volume":"83","author":"SM Hoy","year":"2023","unstructured":"Hoy SM (2023) Rozanolixizumab: first approval. Drugs 83:1341\u20131347. https:\/\/doi.org\/10.1007\/s40265-023-01933-1","journal-title":"Drugs"},{"key":"13225_CR52","doi-asserted-by":"publisher","unstructured":"GreenwoodGT, Lynch Z (2020) Successful Transition from Plasma Exchange to Eculizumab in Acetylcholine Receptor Antibody- and Muscle-Specific Kinase (MuSK) Antibody-Negative Myasthenia Gravis: a case report. Am J Case Rep 21:e921431. https:\/\/doi.org\/10.12659\/AJCR.921431","DOI":"10.12659\/AJCR.921431"},{"key":"13225_CR53","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s40259-020-00443-w","volume":"34","author":"S Alabbad","year":"2020","unstructured":"Alabbad S, AlGaeed M, Sikorski P, Kaminski HJ (2020) Monoclonal antibody-based therapies for myasthenia gravis. BioDrugs 34:557\u2013566. https:\/\/doi.org\/10.1007\/s40259-020-00443-w","journal-title":"BioDrugs"},{"key":"13225_CR54","doi-asserted-by":"publisher","unstructured":"HabibAA, Klink AJ, Muppidi S, Parthan A, Sader SC, Balanean A, Gajra A, Nowak RJ, Howard Jr JF, Group ES (2024) United States clinical practice experience with eculizumab in myasthenia gravis: symptoms, function, and immunosuppressant therapy use. J Neurol 271:6114-6126. https:\/\/doi.org\/10.1007\/s00415-024-12569-w","DOI":"10.1007\/s00415-024-12569-w"},{"key":"13225_CR55","doi-asserted-by":"publisher","first-page":"e671","DOI":"10.1212\/WNL.0000000000201501","volume":"100","author":"V Bril","year":"2023","unstructured":"Bril V, Szczudlik A, Vaitkus A, Rozsa C, Kostera-Pruszczyk A, Hon P, Bednarik J, Tyblova M, Kohler W, Toomsoo T, Nowak RJ, Mozaffar T, Freimer ML, Nicolle MW, Magnus T, Pulley MT, Rivner M, Dimachkie MM, Distad BJ, Pascuzzi RM, Babiar D, Lin J, Querolt Coll M, Griffin R, Mondou E (2023) Randomized double-blind placebo-controlled trial of the corticosteroid-sparing effects of immunoglobulin in myasthenia gravis. Neurology 100:e671\u2013e682. https:\/\/doi.org\/10.1212\/WNL.0000000000201501","journal-title":"Neurology"},{"key":"13225_CR56","doi-asserted-by":"publisher","first-page":"175628642311543","DOI":"10.1177\/17562864231154306","volume":"16","author":"AA Pinto","year":"2023","unstructured":"Pinto AA, De Seze J, Jacob A, Reddel S, Yudina A, Tan K (2023) Comparison of IVIg and TPE efficacy in the treatment of neurological disorders: a systematic literature review. Ther Adv Neurol Disord 16:17562864231154306. https:\/\/doi.org\/10.1177\/17562864231154306","journal-title":"Ther Adv Neurol Disord"},{"key":"13225_CR57","doi-asserted-by":"publisher","unstructured":"Howard JrJF, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Muppidi S, Nowak RJ, O\u2019Brien F, Wang JJ, Mantegazza R, Group RS (2017) Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol 16:976-986. https:\/\/doi.org\/10.1016\/S1474-4422(17)30369-1","DOI":"10.1016\/S1474-4422(17)30369-1"},{"key":"13225_CR58","doi-asserted-by":"publisher","unstructured":"MantegazzaR, Wolfe GI, Muppidi S, Wiendl H, Fujita KP, O\u2019Brien FL, Booth HDE, Howard Jr JF, Group RS (2021) Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension. Neurology 96:e610-e618. https:\/\/doi.org\/10.1212\/WNL.0000000000011207","DOI":"10.1212\/WNL.0000000000011207"},{"key":"13225_CR59","doi-asserted-by":"publisher","unstructured":"MuppidiS, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Nowak RJ, Andersen H, Casasnovas C, de Bleecker JL, Vu TH, Mantegazza R, O\u2019Brien FL, Wang JJ, Fujita KP, Howard Jr JF, Regain G, Study (2019) Long-term safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle Nerve 60:14-24. https:\/\/doi.org\/10.1002\/mus.26447","DOI":"10.1002\/mus.26447"},{"key":"13225_CR60","doi-asserted-by":"publisher","first-page":"1056322","DOI":"10.3389\/fneur.2022.1056322","volume":"13","author":"F Stascheit","year":"2022","unstructured":"Stascheit F, Aigner A, Mergenthaler P, Hotter B, Hoffmann S, Lehnerer S, Meisel C, Meisel A (2022) Serum neurofilament light chain in myasthenia gravis subgroups: an exploratory cohort and case-Control study. Front Neurol 13:1056322. https:\/\/doi.org\/10.3389\/fneur.2022.1056322","journal-title":"Front Neurol"},{"key":"13225_CR61","doi-asserted-by":"publisher","first-page":"6209","DOI":"10.1007\/s00415-024-12588-7","volume":"271","author":"C Pane","year":"2024","unstructured":"Pane C, Di Stefano V, Cuomo N, Sarnataro A, Vinciguerra C, Bevilacqua L, Brighina F, Rini N, Puorro G, Marsili A, Garibaldi M, Fionda L, Sacca F (2024) A real-life experience with eculizumab and efgartigimod in generalized myasthenia gravis patients. J Neurol 271:6209\u20136219. https:\/\/doi.org\/10.1007\/s00415-024-12588-7","journal-title":"J Neurol"},{"key":"13225_CR62","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.jocn.2019.02.004","volume":"63","author":"L Wang","year":"2019","unstructured":"Wang L, Xi J, Zhang S, Wu H, Zhou L, Lu J, Zhang T, Zhao C (2019) Effectiveness and safety of tacrolimus therapy for myasthenia gravis: a single arm meta-analysis. J Clin Neurosci 63:160\u2013167. https:\/\/doi.org\/10.1016\/j.jocn.2019.02.004","journal-title":"J Clin Neurosci"},{"key":"13225_CR63","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s40263-023-01059-8","volume":"38","author":"S Crisafulli","year":"2024","unstructured":"Crisafulli S, Boccanegra B, Carollo M, Bottani E, Mantuano P, Trifiro G, De Luca A (2024) Myasthenia gravis treatment: from old drugs to innovative therapies with a glimpse into the future. CNS Drugs 38:15\u201332. https:\/\/doi.org\/10.1007\/s40263-023-01059-8","journal-title":"CNS Drugs"},{"key":"13225_CR64","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41582-018-0110-z","volume":"15","author":"MC Dalakas","year":"2019","unstructured":"Dalakas MC (2019) Immunotherapy in myasthenia gravis in the era of biologics. Nat Rev Neurol 15:113\u2013124. https:\/\/doi.org\/10.1038\/s41582-018-0110-z","journal-title":"Nat Rev Neurol"},{"key":"13225_CR65","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jocn.2023.11.013","volume":"119","author":"B GomezMancilla","year":"2024","unstructured":"GomezMancilla B, Meriggioli MN, Genge A, Roubenoff R, Espie P, Dupuy C, Hartmann N, Pezous N, Kinhikar A, Tichy M, Dionne A, Vissing J, Andersen H, Schoser B, Meisel A, Jordan B, Devlikamova F, Poverennova I, Stuchevskaya F, Lin TS, Rush JS, Gergely P (2024) Efficacy and safety of iscalimab, a novel anti-CD40 monoclonal antibody, in moderate-to-severe myasthenia gravis: a phase 2 randomized study. J Clin Neurosci 119:76\u201384. https:\/\/doi.org\/10.1016\/j.jocn.2023.11.013","journal-title":"J Clin Neurosci"},{"key":"13225_CR66","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1080\/13543784.2021.2010704","volume":"30","author":"R Chen","year":"2021","unstructured":"Chen R, Zhang N, Gao L, Zhong Y, Xu L, Liu H, Zheng Q, Li L (2021) Quantitative evaluation of drug efficacy in the treatment of myasthenia gravis. Expert Opin Investig Drugs 30:1231\u20131240. https:\/\/doi.org\/10.1080\/13543784.2021.2010704","journal-title":"Expert Opin Investig Drugs"},{"key":"13225_CR67","doi-asserted-by":"publisher","unstructured":"BrandsemaJF, Ginsberg M, Hoshino H, Mimaki M, Nagata S, Rao VK, Ruzhansky K, Suresh N, Tiongson E, Yamanouchi H, Frick G, Hicks E, Liao S, Howard Jr JF, Group MGS (2024) Eculizumab in Adolescent Patients With Refractory Generalized Myasthenia Gravis: a Phase 3, Open-Label, Multicenter Study. Pediatr Neurol 156 198-207. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2024.04.020","DOI":"10.1016\/j.pediatrneurol.2024.04.020"},{"key":"13225_CR68","doi-asserted-by":"publisher","first-page":"3125","DOI":"10.1007\/s00415-021-10428-6","volume":"268","author":"U Hofstadt-van Oy","year":"2021","unstructured":"Hofstadt-van Oy U, Stankovic S, Kelbel C, Oswald D, Larrosa-Lombardi S, Barchfeld T, Cleff U (2021) Complement inhibition initiated recovery of a severe myasthenic crisis with COVID-19. J Neurol 268:3125\u20133128. https:\/\/doi.org\/10.1007\/s00415-021-10428-6","journal-title":"J Neurol"},{"key":"13225_CR69","doi-asserted-by":"publisher","first-page":"109","DOI":"10.5692\/clinicalneurol.cn-001922","volume":"64","author":"Y Kuroda","year":"2024","unstructured":"Kuroda Y, Watanabe G, Satou K, Ono H, Tsukita K, Suzuki Y (2024) Eculizumab led to beneficial clinical course in a patient with generalized myasthenia gravis who developed COVID-19-associated pneumonia. Rinsho Shinkeigaku 64:109\u2013112. https:\/\/doi.org\/10.5692\/clinicalneurol.cn-001922","journal-title":"Rinsho Shinkeigaku"},{"key":"13225_CR70","doi-asserted-by":"publisher","first-page":"4081","DOI":"10.1007\/s10072-022-05922-2","volume":"43","author":"M Mimori","year":"2022","unstructured":"Mimori M, Komatsu T, Maku T, Mitsumura H, Iguchi Y (2022) Generalized myasthenia gravis patients infected with COVID-19 should continue eculizumab. Neurol Sci 43:4081\u20134083. https:\/\/doi.org\/10.1007\/s10072-022-05922-2","journal-title":"Neurol Sci"},{"key":"13225_CR71","doi-asserted-by":"publisher","unstructured":"LeeJW, Sicre de Fontbrune F, Wong Lee Lee L, Pessoa V, Gualandro S, Fureder W, Ptushkin V, Rottinghaus ST, Volles L, Shafner L, Aguzzi R, Pradhan R, Schrezenmeier H, Hill A (2019) Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. Blood 133:530\u2013539. https:\/\/doi.org\/10.1182\/blood-2018-09-876136","DOI":"10.1182\/blood-2018-09-876136"},{"key":"13225_CR72","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0195909","volume":"13","author":"D Sheridan","year":"2018","unstructured":"Sheridan D, Yu ZX, Zhang Y, Patel R, Sun F, Lasaro MA, Bouchard K, Andrien B, Marozsan A, Wang Y, Tamburini P (2018) Design and preclinical characterization of ALXN1210: a novel anti-C5 antibody with extended duration of action. PLoS ONE 13:e0195909. https:\/\/doi.org\/10.1371\/journal.pone.0195909","journal-title":"PLoS ONE"},{"key":"13225_CR73","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.1007\/s00415-023-11617-1","volume":"270","author":"T Vu","year":"2023","unstructured":"Vu T, Ortiz S, Katsuno M, Annane D, Mantegazza R, Beasley KN, Aguzzi R, Howard JF Jr (2023) Ravulizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravis. J Neurol 270:3129\u20133137. https:\/\/doi.org\/10.1007\/s00415-023-11617-1","journal-title":"J Neurol"},{"key":"13225_CR74","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.2147\/NDT.S374694","volume":"19","author":"T Vu","year":"2023","unstructured":"Vu T, Wiendl H, Katsuno M, Reddel SW, Howard JF Jr (2023) Ravulizumab in myasthenia gravis: a review of the current evidence. Neuropsychiatr Dis Treat 19:2639\u20132655. https:\/\/doi.org\/10.2147\/NDT.S374694","journal-title":"Neuropsychiatr Dis Treat"},{"key":"13225_CR75","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-023-00514-4","author":"T Vu","year":"2023","unstructured":"Vu T, Meisel A, Mantegazza R, Annane D, Katsuno M, Aguzzi R, Enayetallah A, Beasley KN, Rampal N, Howard JF Jr (2023) Summary of research: terminal complement inhibitor ravulizumab in generalized myasthenia gravis. Neurol Ther. https:\/\/doi.org\/10.1007\/s40120-023-00514-4","journal-title":"Neurol Ther"},{"key":"13225_CR76","doi-asserted-by":"publisher","unstructured":"MeiselA, Annane D, Vu T, Mantegazza R, Katsuno M, Aguzzi R, Frick G, Gault L, Howard Jr JF, Group CMS (2023) Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension. J Neurol 270:3862-3875. https:\/\/doi.org\/10.1007\/s00415-023-11699-x","DOI":"10.1007\/s00415-023-11699-x"},{"key":"13225_CR77","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1007\/s10072-023-07190-0","volume":"45","author":"L Fionda","year":"2024","unstructured":"Fionda L, Rossini E, Lauletta A, Leonardi L, Tufano L, Costanzo R, Marchetti P, Salvetti M, Garibaldi M, Morino S, Antonini G (2024) Eculizumab for myasthenic exacerbation during treatment with immune-checkpoint inhibitors. Neurol Sci 45:1243\u20131247. https:\/\/doi.org\/10.1007\/s10072-023-07190-0","journal-title":"Neurol Sci"},{"key":"13225_CR78","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1002\/mus.28037","volume":"69","author":"S Zadeh","year":"2024","unstructured":"Zadeh S, Price H, Drews R, Bouffard MA, Young LH, Narayanaswami P (2024) Novel uses of complement inhibitors in myasthenia gravis-Two case reports. Muscle Nerve 69:368\u2013372. https:\/\/doi.org\/10.1002\/mus.28037","journal-title":"Muscle Nerve"},{"key":"13225_CR79","doi-asserted-by":"publisher","first-page":"2898","DOI":"10.1007\/s00415-024-12234-2","volume":"271","author":"FF Konen","year":"2024","unstructured":"Konen FF, Jendretzky KF, Ratuszny D, Schuppner R, Suhs KW, Pawlitzki M, Ruck T, Meuth SG, Skripuletz T (2024) Ravulizumab in myasthenic crisis: the first case report. J Neurol 271:2898\u20132901. https:\/\/doi.org\/10.1007\/s00415-024-12234-2","journal-title":"J Neurol"},{"key":"13225_CR80","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s40272-024-00649-3","volume":"26","author":"S Ramdas","year":"2024","unstructured":"Ramdas S, Painho T, Vanegas MI, Famili DT, Lim MJ, Jungbluth H (2024) Targeted treatments for myasthenia gravis in children and adolescents. Paediatr Drugs 26:719\u2013740. https:\/\/doi.org\/10.1007\/s40272-024-00649-3","journal-title":"Paediatr Drugs"},{"key":"13225_CR81","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1007\/s12325-024-02856-3","volume":"41","author":"C van Steen","year":"2024","unstructured":"van Steen C, Celico L, Spaepen E, Hagenacker T, Meuth SG, Ruck T, Smith AG, Bodicoat DH, de Francesco M, Iannazzo S (2024) Efgartigimod and ravulizumab for treating acetylcholine receptor auto-antibody-positive (AChR-Ab+) generalized myasthenia gravis: indirect treatment comparison. Adv Ther 41:2486\u20132499. https:\/\/doi.org\/10.1007\/s12325-024-02856-3","journal-title":"Adv Ther"},{"key":"13225_CR82","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200331","volume":"12","author":"F Stascheit","year":"2025","unstructured":"Stascheit F, Sousa CDF, Aigner A, Behrens M, Keller CW, Klotz L, Lehnerer S, Stein M, Herdick M, Doksani P, Gerischer LM, Hoffmann S, Lazaridis K, Tzartos J, Wiendl H, Meisel A, Lunemann JD (2025) Ravulizumab and efgartigimod in myasthenia gravis: a real-world study. Neurol Neuroimmunol Neuroinflamm 12:e200331. https:\/\/doi.org\/10.1212\/NXI.0000000000200331","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"13225_CR83","doi-asserted-by":"publisher","first-page":"929","DOI":"10.3324\/haematol.2022.281780","volume":"109","author":"AG Kulasekararaj","year":"2024","unstructured":"Kulasekararaj AG, Lehtinen AE, Forsyth C, Gandhi S, Griffin M, Korper S, Mikala G, Muus P, Overgaard U, Patriquin CJ, Pullon H, Shen YM, Spearing R, Szer J, De la Borderie G, Duda PW, Farzaneh-Far R, Ragunathan S, Sayegh CE, Vadysirisack DD, Schrezenmeier H (2024) Phase II trials of zilucoplan in paroxysmal nocturnal hemoglobinuria. Haematologica 109:929\u2013935. https:\/\/doi.org\/10.3324\/haematol.2022.281780","journal-title":"Haematologica"},{"key":"13225_CR84","doi-asserted-by":"publisher","first-page":"1213920","DOI":"10.3389\/fimmu.2023.1213920","volume":"14","author":"GQ Tang","year":"2023","unstructured":"Tang GQ, Tang Y, Dhamnaskar K, Hoarty MD, Vyasamneni R, Vadysirisack DD, Ma Z, Zhu N, Wang JG, Bu C, Cong B, Palmer E, Duda PW, Sayegh C, Ricardo A (2023) Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation. Front Immunol 14:1213920. https:\/\/doi.org\/10.3389\/fimmu.2023.1213920","journal-title":"Front Immunol"},{"key":"13225_CR85","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s40265-023-01977-3","volume":"84","author":"M Shirley","year":"2024","unstructured":"Shirley M (2024) Zilucoplan: first approval. Drugs 84:99\u2013104. https:\/\/doi.org\/10.1007\/s40265-023-01977-3","journal-title":"Drugs"},{"key":"13225_CR86","doi-asserted-by":"publisher","unstructured":"Howard JrJF, Bresch S, Genge A, Hewamadduma C, Hinton J, Hussain Y, Juntas-Morales R, Kaminski HJ, Maniaol A, Mantegazza R, Masuda M, Sivakumar K, Smilowski M, Utsugisawa K, Vu T, Weiss MD, Zajda M, Boroojerdi B, Brock M, de la Borderie G, Duda PW, Lowcock R, Vanderkelen M, Leite MI, Team RS (2023) Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Neurol 22:395-406. https:\/\/doi.org\/10.1016\/S1474-4422(23)00080-7","DOI":"10.1016\/S1474-4422(23)00080-7"},{"key":"13225_CR87","doi-asserted-by":"publisher","unstructured":"Howard JrJF, Bresch S, Farmakidis C, Freimer M, Genge A, Hewamadduma C, Hinton J, Hussain Y, Juntas-Morales R, Kaminski HJ, Maniaol A, Mantegazza R, Masuda M, Nowak RJ, Sivakumar K, Smilowski M, Utsugisawa K, Vu T, Weiss MD, Zajda M, Bloemers J, Boroojerdi B, Brock M, de la Borderie G, Duda PW, Vanderkelen M, Leite MI, Team* R-XS (2024) Long-term safety and efficacy of zilucoplan in patients with generalized myasthenia gravis: interim analysis of the RAISE-XT open-label extension study. Ther Adv Neurol Disord 17:17562864241243186. https:\/\/doi.org\/10.1177\/17562864241243186","DOI":"10.1177\/17562864241243186"},{"key":"13225_CR88","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1001\/jamaneurol.2019.5125","volume":"77","author":"JF Howard Jr","year":"2020","unstructured":"Howard JF Jr, Nowak RJ, Wolfe GI, Freimer ML, Vu TH, Hinton JL, Benatar M, Duda PW, MacDougall JE, Farzaneh-Far R, Kaminski HJ, Zilucoplan MGSG, Barohn R, Dimachkie M, Pasnoor M, Farmakidis C, Liu T, Colgan S, Benatar MG, Bertorini T, Pillai R, Henegar R, Bromberg M, Gibson S, Janecki T, Freimer M, Elsheikh B, Matisak P, Genge A, Guidon A, David W, Habib AA, Mathew V, Mozaffar T, Hinton JL, Hewitt W, Barnett D, Sullivan P, Ho D, Howard JF Jr, Traub RE, Chopra M, Kaminski HJ, Aly R, Bayat E, Abu-Rub M, Khan S, Lange D, Holzberg S, Khatri B, Lindman E, Olapo T, Sershon LM, Lisak RP, Bernitsas E, Jia K, Malik R, Lewis-Collins TD, Nicolle M, Nowak RJ, Sharma A, Roy B, Nye J, Pulley M, Berger A, Shabbir Y, Sachdev A, Patterson K, Siddiqi Z, Sivak M, Bratton J, Small G, Kohli A, Fetter M, Vu T, Lam L, Harvey B, Wolfe GI, Silvestri N, Patrick K, Zakalik K, Duda PW, MacDougall J, Farzaneh-Far R, Pontius A, Hoarty M (2020) Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial. JAMA Neurol 77:582\u2013592. https:\/\/doi.org\/10.1001\/jamaneurol.2019.5125","journal-title":"JAMA Neurol"},{"key":"13225_CR89","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0231892","volume":"15","author":"A Latuszek","year":"2020","unstructured":"Latuszek A, Liu Y, Olsen O, Foster R, Cao M, Lovric I, Yuan M, Liu N, Chen H, Zhang Q, Xiao H, Springer C, Ehrlich G, Kamat V, Rafique A, Hu Y, Krueger P, Huang T, Poueymirou W, Babb R, Rosconi MP, Retter MW, Chen G, Morton L, Zambrowicz B, Cao J, Romano C, Olson WC (2020) Inhibition of complement pathway activation with Pozelimab, a fully human antibody to complement component C5. PLoS ONE 15:e0231892. https:\/\/doi.org\/10.1371\/journal.pone.0231892","journal-title":"PLoS ONE"},{"key":"13225_CR90","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s40262-020-00940-9","volume":"60","author":"P Badri","year":"2021","unstructured":"Badri P, Jiang X, Borodovsky A, Najafian N, Kim J, Clausen VA, Goel V, Habtemariam B, Robbie GJ (2021) Pharmacokinetic and Pharmacodynamic Properties of Cemdisiran, an RNAi Therapeutic Targeting Complement Component 5, in Healthy Subjects and Patients with Paroxysmal Nocturnal Hemoglobinuria. Clin Pharmacokinet 60:365\u2013378. https:\/\/doi.org\/10.1007\/s40262-020-00940-9","journal-title":"Clin Pharmacokinet"},{"key":"13225_CR91","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0269749","volume":"17","author":"K Devalaraja-Narashimha","year":"2022","unstructured":"Devalaraja-Narashimha K, Huang C, Cao M, Chen YP, Borodovsky A, Olson WC, Morton LG, Retter MW (2022) Pharmacokinetics and pharmacodynamics of pozelimab alone or in combination with cemdisiran in non-human primates. PLoS ONE 17:e0269749. https:\/\/doi.org\/10.1371\/journal.pone.0269749","journal-title":"PLoS ONE"},{"key":"13225_CR92","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s13311-022-01181-3","volume":"19","author":"F Vanoli","year":"2022","unstructured":"Vanoli F, Mantegazza R (2022) Antibody therapies in autoimmune neuromuscular junction disorders: approach to myasthenic crisis and chronic management. Neurotherapeutics 19:897\u2013910. https:\/\/doi.org\/10.1007\/s13311-022-01181-3","journal-title":"Neurotherapeutics"},{"key":"13225_CR93","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ncl.2018.01.011","volume":"36","author":"C Farmakidis","year":"2018","unstructured":"Farmakidis C, Pasnoor M, Dimachkie MM, Barohn RJ (2018) Treatment of myasthenia gravis. Neurol Clin 36:311\u2013337. https:\/\/doi.org\/10.1016\/j.ncl.2018.01.011","journal-title":"Neurol Clin"},{"key":"13225_CR94","doi-asserted-by":"publisher","first-page":"8292","DOI":"10.1074\/jbc.M609858200","volume":"282","author":"NJ Hepburn","year":"2007","unstructured":"Hepburn NJ, Williams AS, Nunn MA, Chamberlain-Banoub JC, Hamer J, Morgan BP, Harris CL (2007) In vivo characterization and therapeutic efficacy of a C5-specific inhibitor from the soft tick Ornithodoros moubata. J Biol Chem 282:8292\u20138299. https:\/\/doi.org\/10.1074\/jbc.M609858200","journal-title":"J Biol Chem"},{"key":"13225_CR95","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/ana.21536","volume":"65","author":"J Soltys","year":"2009","unstructured":"Soltys J, Kusner LL, Young A, Richmonds C, Hatala D, Gong B, Shanmugavel V, Kaminski HJ (2009) Novel complement inhibitor limits severity of experimentally myasthenia gravis. Ann Neurol 65:67\u201375. https:\/\/doi.org\/10.1002\/ana.21536","journal-title":"Ann Neurol"},{"key":"13225_CR96","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1021\/acs.bioconjchem.4c00126","volume":"35","author":"W Shangguan","year":"2024","unstructured":"Shangguan W, Li X, Wang Y, Huang Z, Dong Y, Feng M, Feng J (2024) Design and Biological Evaluation of the Long-Acting C5-Inhibited Ornithodoros moubata Complement Inhibitor (OmCI) Modified with Fatty Acid. Bioconjug Chem 35:653\u2013664. https:\/\/doi.org\/10.1021\/acs.bioconjchem.4c00126","journal-title":"Bioconjug Chem"},{"key":"13225_CR97","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.968206","volume":"13","author":"E Lekova","year":"2022","unstructured":"Lekova E, Zelek WM, Gower D, Spitzfaden C, Osuch IH, John-Morris E, Stach L, Gormley D, Sanderson A, Bridges A, Wear ER, Petit-Frere S, Burden MN, Priest R, Wattam T, Kitchen SJ, Feeney M, Davis S, Morgan BP, Nichols EM (2022) Discovery of functionally distinct anti-C7 monoclonal antibodies and stratification of anti-nicotinic AChR positive Myasthenia Gravis patients. Front Immunol 13:968206. https:\/\/doi.org\/10.3389\/fimmu.2022.968206","journal-title":"Front Immunol"},{"key":"13225_CR98","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.4049\/jimmunol.142.8.2654","volume":"142","author":"G Biesecker","year":"1989","unstructured":"Biesecker G, Gomez CM (1989) Inhibition of acute passive transfer experimental autoimmune myasthenia gravis with Fab antibody to complement C6. J Immunol 142:2654\u20132659","journal-title":"J Immunol"},{"key":"13225_CR99","doi-asserted-by":"publisher","first-page":"2802","DOI":"10.1016\/j.cell.2023.04.031","volume":"186","author":"JV Desai","year":"2023","unstructured":"Desai JV, Kumar D, Freiwald T, Chauss D, Johnson MD, Abers MS, Steinbrink JM, Perfect JR, Alexander B, Matzaraki V, Snarr BD, Zarakas MA, Oikonomou V, Silva LM, Shivarathri R, Beltran E, Demontel LN, Wang L, Lim JK, Launder D, Conti HR, Swamydas M, McClain MT, Moutsopoulos NM, Kazemian M, Netea MG, Kumar V, Kohl J, Kemper C, Afzali B, Lionakis MS (2023) C5a-licensed phagocytes drive sterilizing immunity during systemic fungal infection. Cell 186:2802-2822.e22. https:\/\/doi.org\/10.1016\/j.cell.2023.04.031","journal-title":"Cell"},{"key":"13225_CR100","doi-asserted-by":"publisher","first-page":"1015128","DOI":"10.3389\/fimmu.2022.1015128","volume":"13","author":"J Ye","year":"2022","unstructured":"Ye J, Yang P, Yang Y, Xia S (2022) Complement C1s as a diagnostic marker and therapeutic target: progress and propective. Front Immunol 13:1015128. https:\/\/doi.org\/10.3389\/fimmu.2022.1015128","journal-title":"Front Immunol"},{"key":"13225_CR101","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jneuroim.2006.10.014","volume":"182","author":"E Tuzun","year":"2007","unstructured":"Tuzun E, Li J, Saini SS, Yang H, Christadoss P (2007) Pros and cons of treating murine myasthenia gravis with anti-C1q antibody. J Neuroimmunol 182:167\u2013176. https:\/\/doi.org\/10.1016\/j.jneuroim.2006.10.014","journal-title":"J Neuroimmunol"},{"key":"13225_CR102","doi-asserted-by":"publisher","first-page":"4589","DOI":"10.2147\/JIR.S322391","volume":"14","author":"H Li","year":"2021","unstructured":"Li H, Chen J, Hu Y, Cai X, Tang D, Zhang P (2021) Serum C1q levels have prognostic value for sepsis and are related to the severity of sepsis and organ damage. J Inflamm Res 14:4589\u20134600. https:\/\/doi.org\/10.2147\/JIR.S322391","journal-title":"J Inflamm Res"},{"key":"13225_CR103","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1080\/17474086.2023.2218611","volume":"16","author":"CM Broome","year":"2023","unstructured":"Broome CM (2023) Complement-directed therapy for cold agglutinin disease: sutimlimab. Expert Rev Hematol 16:479\u2013494. https:\/\/doi.org\/10.1080\/17474086.2023.2218611","journal-title":"Expert Rev Hematol"},{"key":"13225_CR104","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1111\/ajt.14528","volume":"18","author":"F Eskandary","year":"2018","unstructured":"Eskandary F, Jilma B, Muhlbacher J, Wahrmann M, Regele H, Kozakowski N, Firbas C, Panicker S, Parry GC, Gilbert JC, Halloran PF, Bohmig GA (2018) Anti-C1s monoclonal antibody BIVV009 in late antibody-mediated kidney allograft rejection-results from a first-in-patient phase 1 trial. Am J Transplant 18:916\u2013926. https:\/\/doi.org\/10.1111\/ajt.14528","journal-title":"Am J Transplant"},{"key":"13225_CR105","doi-asserted-by":"publisher","first-page":"3847","DOI":"10.4049\/jimmunol.171.7.3847","volume":"171","author":"E Tuzun","year":"2003","unstructured":"Tuzun E, Scott BG, Goluszko E, Higgs S, Christadoss P (2003) Genetic evidence for involvement of classical complement pathway in induction of experimental autoimmune myasthenia gravis. J Immunol 171:3847\u20133854. https:\/\/doi.org\/10.4049\/jimmunol.171.7.3847","journal-title":"J Immunol"},{"key":"13225_CR106","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jaut.2013.01.003","volume":"42","author":"R Huda","year":"2013","unstructured":"Huda R, Tuzun E, Christadoss P (2013) Complement C2 siRNA mediated therapy of myasthenia gravis in mice. J Autoimmun 42:94\u2013104. https:\/\/doi.org\/10.1016\/j.jaut.2013.01.003","journal-title":"J Autoimmun"},{"key":"13225_CR107","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jneuroim.2008.12.013","volume":"208","author":"J Li","year":"2009","unstructured":"Li J, Qi H, Tuzun E, Allman W, Yilmaz V, Saini SS, Deymeer F, Saruhan-Direskeneli G, Christadoss P (2009) Mannose-binding lectin pathway is not involved in myasthenia gravis pathogenesis. J Neuroimmunol 208:40\u201345. https:\/\/doi.org\/10.1016\/j.jneuroim.2008.12.013","journal-title":"J Neuroimmunol"},{"key":"13225_CR108","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22179580","author":"H Murray","year":"2021","unstructured":"Murray H, Qiu B, Ho SY, Wang X (2021) Complement Factor B Mediates Ocular Angiogenesis through Regulating the VEGF Signaling Pathway. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms22179580","journal-title":"Int J Mol Sci"},{"key":"13225_CR109","doi-asserted-by":"publisher","first-page":"5567","DOI":"10.4049\/jimmunol.1402013","volume":"193","author":"M Subias","year":"2014","unstructured":"Subias M, Tortajada A, Gastoldi S, Galbusera M, Lopez-Perrote A, Lopez Lde J, Gonzalez-Fernandez FA, Villegas-Martinez A, Dominguez M, Llorca O, Noris M, Morgan BP, Rodriguez de Cordoba S (2014) A novel antibody against human factor B that blocks formation of the C3bB proconvertase and inhibits complement activation in disease models. J Immunol 193:5567\u20135575. https:\/\/doi.org\/10.4049\/jimmunol.1402013","journal-title":"J Immunol"},{"key":"13225_CR110","doi-asserted-by":"publisher","unstructured":"Peffault de LatourR, Roth A, Kulasekararaj AG, Han B, Scheinberg P, Maciejewski JP, Ueda Y, de Castro CM, Di Bona E, Fu R, Zhang L, Griffin M, Langemeijer SMC, Panse J, Schrezenmeier H, Barcellini W, Mauad VAQ, Schafhausen P, Tavitian S, Beggiato E, Chew LP, Gaya A, Huang WH, Jang JH, Kitawaki T, Kutlar A, Notaro R, Pullarkat V, Schubert J, Terriou L, Uchiyama M, Wong Lee Lee L, Yap ES, Sicre de Fontbrune F, Marano L, Alashkar F, Gandhi S, Trikha R, Yang C, Liu H, Kelly RJ, Hochsmann B, Kerloeguen C, Banerjee P, Levitch R, Kumar R, Wang Z, Thorburn C, Maitra S, Li S, Verles A, Dahlke M, Risitano AM (2024) Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria. N Engl J Med 390:994\u20131008. https:\/\/doi.org\/10.1056\/NEJMoa2308695","DOI":"10.1056\/NEJMoa2308695"},{"key":"13225_CR111","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1080\/17474086.2024.2422558","volume":"17","author":"E Muvaffak","year":"2024","unstructured":"Muvaffak E, Mokresh ME, Varda A, Lakmoush M, Ilter MK (2024) Safety and efficacy of danicopan in patients with paroxysmal nocturnal hemoglobinuria: a systematic review and meta-analysis. Expert Rev Hematol 17:819\u2013831. https:\/\/doi.org\/10.1080\/17474086.2024.2422558","journal-title":"Expert Rev Hematol"},{"key":"13225_CR112","doi-asserted-by":"publisher","first-page":"ii28","DOI":"10.1093\/ckj\/sfad198","volume":"16","author":"F Caravaca-Fontan","year":"2023","unstructured":"Caravaca-Fontan F, Gutierrez E, Sevillano AM, Praga M (2023) Targeting complement in IgA nephropathy. Clin Kidney J 16:ii28\u2013ii39. https:\/\/doi.org\/10.1093\/ckj\/sfad198","journal-title":"Clin Kidney J"},{"issue":"Suppl 1","key":"13225_CR113","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/ijlh.14281","volume":"46","author":"F Versino","year":"2024","unstructured":"Versino F, Fattizzo B (2024) Complement inhibition in paroxysmal nocturnal hemoglobinuria: from biology to therapy. Int J Lab Hematol 46(Suppl 1):43\u201354. https:\/\/doi.org\/10.1111\/ijlh.14281","journal-title":"Int J Lab Hematol"},{"key":"13225_CR114","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/imr.13147","volume":"313","author":"A Zarantonello","year":"2023","unstructured":"Zarantonello A, Revel M, Grunenwald A, Roumenina LT (2023) C3-dependent effector functions of complement. Immunol Rev 313:120\u2013138. https:\/\/doi.org\/10.1111\/imr.13147","journal-title":"Immunol Rev"},{"key":"13225_CR115","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1002\/mus.21398","volume":"40","author":"A Liu","year":"2009","unstructured":"Liu A, Lin H, Liu Y, Cao X, Wang X, Li Z (2009) Correlation of C3 level with severity of generalized myasthenia gravis. Muscle Nerve 40:801\u2013808. https:\/\/doi.org\/10.1002\/mus.21398","journal-title":"Muscle Nerve"},{"key":"13225_CR116","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1196\/annals.1405.009","volume":"1132","author":"P Christadoss","year":"2008","unstructured":"Christadoss P, Tuzun E, Li J, Saini SS, Yang H (2008) Classical complement pathway in experimental autoimmune myasthenia gravis pathogenesis. Ann N Y Acad Sci 1132:210\u2013219. https:\/\/doi.org\/10.1196\/annals.1405.009","journal-title":"Ann N Y Acad Sci"},{"key":"13225_CR117","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1007\/s40265-021-01560-8","volume":"81","author":"SM Hoy","year":"2021","unstructured":"Hoy SM (2021) Pegcetacoplan: first approval. Drugs 81:1423\u20131430. https:\/\/doi.org\/10.1007\/s40265-021-01560-8","journal-title":"Drugs"},{"key":"13225_CR118","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1056\/NEJMoa2029073","volume":"384","author":"P Hillmen","year":"2021","unstructured":"Hillmen P, Szer J, Weitz I, Roth A, Hochsmann B, Panse J, Usuki K, Griffin M, Kiladjian JJ, de Castro C, Nishimori H, Tan L, Hamdani M, Deschatelets P, Francois C, Grossi F, Ajayi T, Risitano A, Peffault de Latour R (2021) Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria. N Engl J Med 384:1028\u20131037. https:\/\/doi.org\/10.1056\/NEJMoa2029073","journal-title":"N Engl J Med"},{"key":"13225_CR119","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.19082\/1718","volume":"8","author":"MN Hamdoon","year":"2016","unstructured":"Hamdoon MN, Fattouh M, El-Din AN, Elnady HM (2016) The potential role of cell surface complement regulators and circulating CD4+ CD25+ T cells in the development of autoimmune myasthenia gravis. Electron Physician 8:1718\u20131726. https:\/\/doi.org\/10.19082\/1718","journal-title":"Electron Physician"},{"key":"13225_CR120","doi-asserted-by":"publisher","first-page":"1290684","DOI":"10.3389\/fimmu.2023.1290684","volume":"14","author":"FQ An","year":"2023","unstructured":"An FQ, Zhou G, Harland MT, Hussain W, Strainic MG, Jain MK, Medof ME (2023) KLF4 and CD55 expression and function depend on each other. Front Immunol 14:1290684. https:\/\/doi.org\/10.3389\/fimmu.2023.1290684","journal-title":"Front Immunol"},{"issue":"4","key":"13225_CR121","doi-asserted-by":"publisher","first-page":"e769","DOI":"10.34067\/KID.0000000000000122","volume":"360","author":"KL Budge","year":"2023","unstructured":"Budge KL, Verlato A, Bin S, Salem FE, Perin L, La Manna G, Zaza G, Fiaccadori E, Cantarelli C, Cravedi P (2023) Decay-accelerating factor restrains complement activation and delays progression of murine cbsa-induced membranous nephropathy. Kidney 360(4):e769\u2013e776. https:\/\/doi.org\/10.34067\/KID.0000000000000122","journal-title":"Kidney"},{"key":"13225_CR122","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.15794","volume":"11","author":"D Murad","year":"2023","unstructured":"Murad D, Zafar Paracha R, Saeed MT, Ahmad J, Mushtaq A, Humayun M (2023) Modelling and analysis of the complement system signalling pathways: roles of C3, C5a and pro-inflammatory cytokines in SARS-CoV-2 infection. PeerJ 11:e15794. https:\/\/doi.org\/10.7717\/peerj.15794","journal-title":"PeerJ"},{"key":"13225_CR123","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1172\/JCI16086","volume":"110","author":"F Lin","year":"2002","unstructured":"Lin F, Kaminski HJ, Conti-Fine BM, Wang W, Richmonds C, Medof ME (2002) Markedly enhanced susceptibility to experimental autoimmune myasthenia gravis in the absence of decay-accelerating factor protection. J Clin Invest 110:1269\u20131274. https:\/\/doi.org\/10.1172\/JCI16086","journal-title":"J Clin Invest"},{"key":"13225_CR124","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.89665","volume":"2","author":"M Sudres","year":"2017","unstructured":"Sudres M, Maurer M, Robinet M, Bismuth J, Truffault F, Girard D, Dragin N, Attia M, Fadel E, Santelmo N, Sicsic C, Brenner T, Berrih-Aknin S (2017) Preconditioned mesenchymal stem cells treat myasthenia gravis in a humanized preclinical model. JCI Insight 2:e89665. https:\/\/doi.org\/10.1172\/jci.insight.89665","journal-title":"JCI Insight"},{"key":"13225_CR125","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1002\/mus.24057","volume":"49","author":"LL Kusner","year":"2014","unstructured":"Kusner LL, Satija N, Cheng G, Kaminski HJ (2014) Targeting therapy to the neuromuscular junction: proof of concept. Muscle Nerve 49:749\u2013756. https:\/\/doi.org\/10.1002\/mus.24057","journal-title":"Muscle Nerve"},{"key":"13225_CR126","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1038\/s41467-023-36441-z","volume":"14","author":"EC Couves","year":"2023","unstructured":"Couves EC, Gardner S, Voisin TB, Bickel JK, Stansfeld PJ, Tate EW, Bubeck D (2023) Structural basis for membrane attack complex inhibition by CD59. Nat Commun 14:890. https:\/\/doi.org\/10.1038\/s41467-023-36441-z","journal-title":"Nat Commun"},{"key":"13225_CR127","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.jcyt.2021.12.003","volume":"24","author":"JT Loh","year":"2022","unstructured":"Loh JT, Zhang B, Teo JKH, Lai RC, Choo ABH, Lam KP, Lim SK (2022) Mechanism for the attenuation of neutrophil and complement hyperactivity by MSC exosomes. Cytotherapy 24:711\u2013719. https:\/\/doi.org\/10.1016\/j.jcyt.2021.12.003","journal-title":"Cytotherapy"},{"key":"13225_CR128","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200057","author":"K Iwasa","year":"2023","unstructured":"Iwasa K, Furukawa Y, Yoshikawa H, Yamada M, Ono K (2023) CD59 Expression in Skeletal Muscles and Its Role in Myasthenia Gravis. Neurol Neuroimmunol Neuroinflamm. https:\/\/doi.org\/10.1212\/NXI.0000000000200057","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"13225_CR129","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001169","author":"AH Obaid","year":"2022","unstructured":"Obaid AH, Zografou C, Vadysirisack DD, Munro-Sheldon B, Fichtner ML, Roy B, Philbrick WM, Bennett JL, Nowak RJ, O\u2019Connor KC (2022) Heterogeneity of acetylcholine receptor autoantibody-mediated complement activity in patients with myasthenia gravis. Neurol Neuroimmunol Neuroinflamm. https:\/\/doi.org\/10.1212\/NXI.0000000000001169","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"13225_CR130","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202300571R","volume":"37","author":"L Gonzalez-Del-Barrio","year":"2023","unstructured":"Gonzalez-Del-Barrio L, Perez-Alos L, Cyranka L, Rosbjerg A, Nagy S, Prohaszka Z, Garred P, Bayarri-Olmos R (2023) MAP-2:CD55 chimeric construct effectively modulates complement activation. FASEB J 37:e23256. https:\/\/doi.org\/10.1096\/fj.202300571R","journal-title":"FASEB J"},{"key":"13225_CR131","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1089\/jop.2016.0101","volume":"33","author":"G Schnabolk","year":"2017","unstructured":"Schnabolk G, Beon MK, Tomlinson S, Rohrer B (2017) New Insights on Complement Inhibitor CD59 in Mouse laser-induced choroidal neovascularization: mislocalization after injury and targeted delivery for protein replacement. J Ocul Pharmacol Ther 33:400\u2013411. https:\/\/doi.org\/10.1089\/jop.2016.0101","journal-title":"J Ocul Pharmacol Ther"},{"key":"13225_CR132","doi-asserted-by":"publisher","first-page":"17377","DOI":"10.1038\/s41598-023-44512-w","volume":"13","author":"NT Diep","year":"2023","unstructured":"Diep NT, Giang NT, Diu NTT, Nam NM, Khanh LV, Quang HV, Hang NT, Mao CV, Son HV, Hieu NL, Linh PT, Sklan EH, Toan NL, Tong HV (2023) Complement receptor type 1 and 2 (CR1 and CR2) gene polymorphisms and plasma protein levels are associated with the Dengue disease severity. Sci Rep 13:17377. https:\/\/doi.org\/10.1038\/s41598-023-44512-w","journal-title":"Sci Rep"},{"key":"13225_CR133","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.14348\/molcells.2020.0197","volume":"43","author":"J Choi","year":"2020","unstructured":"Choi J, Buyannemekh D, Nham SU (2020) Moieties of Complement iC3b Recognized by the I-domain of Integrin alphaXbeta2. Mol Cells 43:1023\u20131034. https:\/\/doi.org\/10.14348\/molcells.2020.0197","journal-title":"Mol Cells"},{"key":"13225_CR134","doi-asserted-by":"publisher","first-page":"S225","DOI":"10.33549\/physiolres.935175","volume":"72","author":"S Hresko","year":"2023","unstructured":"Hresko S, Madarova M, Dobosova M, Palusekova N, Niznerova P, Ziaran S, Varga I (2023) The Diagnostic Significance of C3d Antigen in Kidney and Skin Histopathology\u2014the Current State-Of-The-Art and Practical Examples. Physiol Res 72:S225\u2013S232. https:\/\/doi.org\/10.33549\/physiolres.935175","journal-title":"Physiol Res"},{"key":"13225_CR135","doi-asserted-by":"publisher","first-page":"1239146","DOI":"10.3389\/fimmu.2023.1239146","volume":"14","author":"J Santos-Lopez","year":"2023","unstructured":"Santos-Lopez J, de la Paz K, Fernandez FJ, Vega MC (2023) Structural biology of complement receptors. Front Immunol 14:1239146. https:\/\/doi.org\/10.3389\/fimmu.2023.1239146","journal-title":"Front Immunol"},{"key":"13225_CR136","doi-asserted-by":"publisher","first-page":"24214","DOI":"10.1073\/pnas.1913443116","volume":"116","author":"G Liu","year":"2019","unstructured":"Liu G, Fu Y, Yosri M, Chen Y, Sun P, Xu J, Zhang M, Sun D, Strickland AB, Mackey ZB, Shi M (2019) CRIg plays an essential role in intravascular clearance of bloodborne parasites by interacting with complement. Proc Natl Acad Sci USA 116:24214\u201324220. https:\/\/doi.org\/10.1073\/pnas.1913443116","journal-title":"Proc Natl Acad Sci USA"},{"key":"13225_CR137","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.840510","volume":"13","author":"AG Small","year":"2022","unstructured":"Small AG, Perveen K, Putty T, Patel N, Quinn P, Wechalekar MD, Hii CS, Quach A, Ferrante A (2022) Neutrophils require activation to express functional cell-surface complement receptor immunoglobulin. Front Immunol 13:840510. https:\/\/doi.org\/10.3389\/fimmu.2022.840510","journal-title":"Front Immunol"},{"key":"13225_CR138","doi-asserted-by":"publisher","first-page":"27657","DOI":"10.1074\/jbc.M002903200","volume":"275","author":"TS Jokiranta","year":"2000","unstructured":"Jokiranta TS, Hellwage J, Koistinen V, Zipfel PF, Meri S (2000) Each of the three binding sites on complement factor H interacts with a distinct site on C3b. J Biol Chem 275:27657\u201327662. https:\/\/doi.org\/10.1074\/jbc.M002903200","journal-title":"J Biol Chem"},{"key":"13225_CR139","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.746068","volume":"13","author":"J Song","year":"2022","unstructured":"Song J, Zhao R, Yan C, Luo S, Xi J, Ding P, Li L, Hu W, Zhao C (2022) A Targeted Complement Inhibitor CRIg\/FH protects against experimental autoimmune myasthenia gravis in rats via immune modulation. Front Immunol 13:746068. https:\/\/doi.org\/10.3389\/fimmu.2022.746068","journal-title":"Front Immunol"},{"key":"13225_CR140","doi-asserted-by":"publisher","DOI":"10.1101\/2023.11.20.23298462","author":"R Skitchenko","year":"2023","unstructured":"Skitchenko R, Modrusan Z, Loboda A, Kopp JB, Winkler CA, Sergushichev A, Gupta N, Stevens C, Daly MJ, Shaw A, Artomov M (2023) CR1 variants contribute to FSGS susceptibility across multiple populations. medRxiv. https:\/\/doi.org\/10.1101\/2023.11.20.23298462","journal-title":"medRxiv"},{"key":"13225_CR141","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/s0165-5728(96)00144-0","volume":"71","author":"SJ Piddlesden","year":"1996","unstructured":"Piddlesden SJ, Jiang S, Levin JL, Vincent A, Morgan BP (1996) Soluble complement receptor 1 (sCR1) protects against experimental autoimmune myasthenia gravis. J Neuroimmunol 71:173\u2013177. https:\/\/doi.org\/10.1016\/s0165-5728(96)00144-0","journal-title":"J Neuroimmunol"},{"key":"13225_CR142","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0236968","volume":"15","author":"M Banadakoppa","year":"2020","unstructured":"Banadakoppa M, Pennington K, Balakrishnan M, Yallampalli C (2020) Complement inhibitor Crry expression in mouse placenta is essential for maintaining normal blood pressure and fetal growth. PLoS ONE 15:e0236968. https:\/\/doi.org\/10.1371\/journal.pone.0236968","journal-title":"PLoS ONE"},{"key":"13225_CR143","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.4103\/1673-5374.332160","volume":"17","author":"XC Zhu","year":"2022","unstructured":"Zhu XC, Liu L, Dai WZ, Ma T (2022) Crry silencing alleviates Alzheimer\u2019s disease injury by regulating neuroinflammatory cytokines and the complement system. Neural Regen Res 17:1841\u20131849. https:\/\/doi.org\/10.4103\/1673-5374.332160","journal-title":"Neural Regen Res"},{"key":"13225_CR144","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1476-9255-9-20","volume":"9","author":"J Soltys","year":"2012","unstructured":"Soltys J, Wu X (2012) Complement regulatory protein Crry deficiency contributes to the antigen specific recall response in experimental autoimmune myasthenia gravis. J Inflamm (Lond) 9:20. https:\/\/doi.org\/10.1186\/1476-9255-9-20","journal-title":"J Inflamm (Lond)"},{"key":"13225_CR145","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.molimm.2007.06.144","volume":"45","author":"NJ Hepburn","year":"2008","unstructured":"Hepburn NJ, Chamberlain-Banoub JL, Williams AS, Morgan BP, Harris CL (2008) Prevention of experimental autoimmune myasthenia gravis by rat Crry-Ig: a model agent for long-term complement inhibition in vivo. Mol Immunol 45:395\u2013405. https:\/\/doi.org\/10.1016\/j.molimm.2007.06.144","journal-title":"Mol Immunol"},{"key":"13225_CR146","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/s41586-024-08395-9","volume":"638","author":"F Lan","year":"2025","unstructured":"Lan F, Li J, Miao W, Sun F, Duan S, Song Y, Yao J, Wang X, Wang C, Liu X, Wang J, Zhang L, Qi H (2025) GZMK-expressing CD8(+) T cells promote recurrent airway inflammatory diseases. Nature 638:490\u2013498. https:\/\/doi.org\/10.1038\/s41586-024-08395-9","journal-title":"Nature"},{"key":"13225_CR147","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1159\/000500545","volume":"12","author":"B van den Broek","year":"2020","unstructured":"van den Broek B, van der Flier M, de Groot R, de Jonge MI, Langereis JD (2020) Common genetic variants in the complement system and their potential link with disease susceptibility and outcome of invasive bacterial infection. J Innate Immun 12:131\u2013141. https:\/\/doi.org\/10.1159\/000500545","journal-title":"J Innate Immun"},{"key":"13225_CR148","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1159\/000491439","volume":"10","author":"DAC Heesterbeek","year":"2018","unstructured":"Heesterbeek DAC, Angelier ML, Harrison RA, Rooijakkers SHM (2018) Complement and bacterial infections: from molecular mechanisms to therapeutic applications. J Innate Immun 10:455\u2013464. https:\/\/doi.org\/10.1159\/000491439","journal-title":"J Innate Immun"},{"key":"13225_CR149","doi-asserted-by":"publisher","DOI":"10.1128\/MMBR.00177-20","author":"E Bjanes","year":"2021","unstructured":"Bjanes E, Nizet V (2021) More than a pore: nonlytic antimicrobial functions of complement and bacterial strategies for evasion. Microbiol Mol Biol Rev. https:\/\/doi.org\/10.1128\/MMBR.00177-20","journal-title":"Microbiol Mol Biol Rev"},{"key":"13225_CR150","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232415586","author":"H Bai","year":"2022","unstructured":"Bai H, Mu L, Qiu L, Chen N, Li J, Zeng Q, Yin X, Ye J (2022) Complement C3 regulates inflammatory response and monocyte\/macrophage phagocytosis of streptococcus agalactiae in a teleost fish. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms232415586","journal-title":"Int J Mol Sci"},{"key":"13225_CR151","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.862935","volume":"12","author":"A Mikucki","year":"2022","unstructured":"Mikucki A, McCluskey NR, Kahler CM (2022) The Host-Pathogen Interactions and Epicellular Lifestyle of Neisseria meningitidis. Front Cell Infect Microbiol 12:862935. https:\/\/doi.org\/10.3389\/fcimb.2022.862935","journal-title":"Front Cell Infect Microbiol"},{"key":"13225_CR152","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.1093\/brain\/awz222","volume":"142","author":"DLH Koelman","year":"2019","unstructured":"Koelman DLH, Brouwer MC, van de Beek D (2019) Targeting the complement system in bacterial meningitis. Brain 142:3325\u20133337. https:\/\/doi.org\/10.1093\/brain\/awz222","journal-title":"Brain"},{"key":"13225_CR153","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/bjh.15790","volume":"185","author":"G Socie","year":"2019","unstructured":"Socie G, Caby-Tosi MP, Marantz JL, Cole A, Bedrosian CL, Gasteyger C, Mujeebuddin A, Hillmen P, Vande Walle J, Haller H (2019) Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis. Br J Haematol 185:297\u2013310. https:\/\/doi.org\/10.1111\/bjh.15790","journal-title":"Br J Haematol"},{"key":"13225_CR154","doi-asserted-by":"publisher","first-page":"1269325","DOI":"10.3389\/fimmu.2023.1269325","volume":"14","author":"N Galli","year":"2023","unstructured":"Galli N, Pettine L, Panigada M, Daprai L, Suriano G, Grancini A, Barcellini W, Fattizzo B (2023) Non-capsulated Neisseria meningitidis sepsis in a paroxysmal nocturnal hemoglobinuria patient treated with ravulizumab: case report and review of the literature. Front Immunol 14:1269325. https:\/\/doi.org\/10.3389\/fimmu.2023.1269325","journal-title":"Front Immunol"},{"key":"13225_CR155","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6909a1","volume":"69","author":"SA Mbaeyi","year":"2020","unstructured":"Mbaeyi SA, Bozio CH, Duffy J, Rubin LG, Hariri S, Stephens DS, MacNeil JR (2020) Meningococcal vaccination: recommendations of the advisory committee on immunization practices, United States, 2020. MMWR Recomm Rep 69:1\u201341. https:\/\/doi.org\/10.15585\/mmwr.rr6909a1","journal-title":"MMWR Recomm Rep"},{"key":"13225_CR156","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.696385","volume":"12","author":"JPR Monteleone","year":"2021","unstructured":"Monteleone JPR, Gao X, Kleijn HJ, Bellanti F, Pelto R (2021) Eculizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravis. Front Neurol 12:696385. https:\/\/doi.org\/10.3389\/fneur.2021.696385","journal-title":"Front Neurol"},{"key":"13225_CR157","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1080\/14712598.2024.2423002","volume":"24","author":"DT Balaban","year":"2024","unstructured":"Balaban DT, Levy M, Borrow R, Anderson MR (2024) An evaluation of ravulizumab for the treatment of neuromyelitis optica spectrum disorder. Expert Opin Biol Ther 24:1193\u20131198. https:\/\/doi.org\/10.1080\/14712598.2024.2423002","journal-title":"Expert Opin Biol Ther"},{"key":"13225_CR158","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/QCO.0000000000000279","volume":"29","author":"E Benamu","year":"2016","unstructured":"Benamu E, Montoya JG (2016) Infections associated with the use of eculizumab: recommendations for prevention and prophylaxis. Curr Opin Infect Dis 29:319\u2013329. https:\/\/doi.org\/10.1097\/QCO.0000000000000279","journal-title":"Curr Opin Infect Dis"},{"key":"13225_CR159","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1007\/s00467-011-1929-3","volume":"26","author":"A Bouts","year":"2011","unstructured":"Bouts A, Monnens L, Davin JC, Struijk G, Spanjaard L (2011) Insufficient protection by Neisseria meningitidis vaccination alone during eculizumab therapy. Pediatr Nephrol 26:1919\u20131920. https:\/\/doi.org\/10.1007\/s00467-011-1929-3","journal-title":"Pediatr Nephrol"},{"key":"13225_CR160","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.913292","volume":"12","author":"R Baerentsen","year":"2022","unstructured":"Baerentsen R, Tang CM, Exley RM (2022) Et tu, Neisseria? Conflicts of Interest Between Neisseria Species, Front Cell Infect Microbiol 12:913292. https:\/\/doi.org\/10.3389\/fcimb.2022.913292","journal-title":"Conflicts of Interest Between Neisseria Species, Front Cell Infect Microbiol"},{"key":"13225_CR161","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.25640","volume":"14","author":"RK Dhanoa","year":"2022","unstructured":"Dhanoa RK, Selvaraj R, Shoukrie SI, Zahra A, Malla J, Selvamani TY, Venugopal S, Hamouda RK, Hamid P (2022) Eculizumab\u2019s unintentional mayhem: a systematic review. Cureus 14:e25640. https:\/\/doi.org\/10.7759\/cureus.25640","journal-title":"Cureus"},{"key":"13225_CR162","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.jmii.2020.06.013","volume":"53","author":"ZY Yu","year":"2020","unstructured":"Yu ZY, Tsai MJ, Lin YJ, Liu WD, Chou SC, Hung CC (2020) Disseminated gonococcal infection in a patient with paroxysmal nocturnal hemoglobinuria having received ravulizumab and meningococcal vaccine. J Microbiol Immunol Infect 53:660\u2013662. https:\/\/doi.org\/10.1016\/j.jmii.2020.06.013","journal-title":"J Microbiol Immunol Infect"},{"key":"13225_CR163","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2024.2392885","author":"Z Zhang","year":"2024","unstructured":"Zhang Z, Liu X, Zhang J, Zhang B (2024) Real-world safety profile of eculizumab: an analysis of FDA adverse event reporting system and systematic review of case reports. Expert Opin Drug Saf. https:\/\/doi.org\/10.1080\/14740338.2024.2392885","journal-title":"Expert Opin Drug Saf"},{"key":"13225_CR164","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/QCO.0000000000000992","volume":"37","author":"A Waltmann","year":"2024","unstructured":"Waltmann A, Chen JS, Duncan JA (2024) Promising developments in gonococcal vaccines. Curr Opin Infect Dis 37:63\u201369. https:\/\/doi.org\/10.1097\/QCO.0000000000000992","journal-title":"Curr Opin Infect Dis"},{"key":"13225_CR165","doi-asserted-by":"publisher","first-page":"S42","DOI":"10.1016\/j.vaccine.2023.01.053","volume":"42","author":"Y Lyu","year":"2024","unstructured":"Lyu Y, Choong A, Chow EPF, Seib KL, Marshall HS, Unemo M, de Voux A, Wang B, Miranda AE, Gottlieb SL, Mello MB, Wi T, Baggaley R, Marshall C, Abu-Raddad LJ, Abara WE, Chen XS, Ong JJ (2024) Vaccine value profile for Neisseria gonorrhoeae. Vaccine 42:S42\u2013S69. https:\/\/doi.org\/10.1016\/j.vaccine.2023.01.053","journal-title":"Vaccine"},{"key":"13225_CR166","doi-asserted-by":"publisher","first-page":"e493","DOI":"10.1097\/MPH.0000000000002075","volume":"44","author":"SH Graciaa","year":"2022","unstructured":"Graciaa SH, Graciaa DS, Yildirim I, Chonat S (2022) Risk of disseminated gonococcal infections with terminal complement blockade. J Pediatr Hematol Oncol 44:e493\u2013e495. https:\/\/doi.org\/10.1097\/MPH.0000000000002075","journal-title":"J Pediatr Hematol Oncol"},{"key":"13225_CR167","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/j.1749-6632.2009.04633.x","volume":"1173","author":"HD Pettigrew","year":"2009","unstructured":"Pettigrew HD, Teuber SS, Gershwin ME (2009) Clinical significance of complement deficiencies. Ann NY Acad Sci 1173:108\u2013123. https:\/\/doi.org\/10.1111\/j.1749-6632.2009.04633.x","journal-title":"Ann NY Acad Sci"},{"key":"13225_CR168","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1016\/j.molimm.2011.05.001","volume":"48","author":"L Skattum","year":"2011","unstructured":"Skattum L, van Deuren M, van der Poll T, Truedsson L (2011) Complement deficiency states and associated infections. Mol Immunol 48:1643\u20131655. https:\/\/doi.org\/10.1016\/j.molimm.2011.05.001","journal-title":"Mol Immunol"},{"key":"13225_CR169","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1159\/000511957","volume":"13","author":"T Vu","year":"2021","unstructured":"Vu T, Harvey B, Suresh N, Farias J, Gooch C (2021) Eculizumab during pregnancy in a patient with treatment-refractory myasthenia gravis: a case report. Case Rep Neurol 13:65\u201372. https:\/\/doi.org\/10.1159\/000511957","journal-title":"Case Rep Neurol"},{"key":"13225_CR170","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1056\/NEJMoa1502950","volume":"373","author":"RJ Kelly","year":"2015","unstructured":"Kelly RJ, Hochsmann B, Szer J, Kulasekararaj A, de Guibert S, Roth A, Weitz IC, Armstrong E, Risitano AM, Patriquin CJ, Terriou L, Muus P, Hill A, Turner MP, Schrezenmeier H, Peffault de Latour R (2015) Eculizumab in pregnant patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 373:1032\u20131039. https:\/\/doi.org\/10.1056\/NEJMoa1502950","journal-title":"N Engl J Med"},{"key":"13225_CR171","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1080\/14737175.2023.2178302","volume":"23","author":"NE Gilhus","year":"2023","unstructured":"Gilhus NE (2023) Treatment considerations in myasthenia gravis for the pregnant patient. Expert Rev Neurother 23:169\u2013177. https:\/\/doi.org\/10.1080\/14737175.2023.2178302","journal-title":"Expert Rev Neurother"},{"key":"13225_CR172","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1007\/s00467-019-04234-6","volume":"34","author":"M Mauras","year":"2019","unstructured":"Mauras M, Bacchetta J, Duncan A, Lavocat MP, Rohmer B, Javouhey E, Collardeau-Frachon S, Sellier-Leclerc AL (2019) Escherichia coli-associated hemolytic uremic syndrome and severe chronic hepatocellular cholestasis: Complication or side effect of eculizumab? Pediatr Nephrol 34:1289\u20131293. https:\/\/doi.org\/10.1007\/s00467-019-04234-6","journal-title":"Pediatr Nephrol"},{"key":"13225_CR173","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2020.579607","volume":"8","author":"D Kelen","year":"2020","unstructured":"Kelen D, Chiodini B, Godart V, Adams B, Stordeur P, Ismaili K (2020) Case Report: neonatal Unexplained HUS Treated With Complement Inhibitor Eculizumab. Front Pediatr 8:579607. https:\/\/doi.org\/10.3389\/fped.2020.579607","journal-title":"Front Pediatr"},{"key":"13225_CR174","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1016\/j.jaip.2019.03.027","volume":"7","author":"R Lo","year":"2019","unstructured":"Lo R, Alexander S, Moss J, Siddiqi A, Liu A (2019) Eculizumab hypersensitivity and desensitization in a toddler with atypical hemolytic uremic syndrome. J Allergy Clin Immunol Pract 7:2409\u20132410. https:\/\/doi.org\/10.1016\/j.jaip.2019.03.027","journal-title":"J Allergy Clin Immunol Pract"},{"key":"13225_CR175","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1016\/j.ekir.2019.07.016","volume":"4","author":"E Rondeau","year":"2019","unstructured":"Rondeau E, Cataland SR, Al-Dakkak I, Miller B, Webb NJA, Landau D (2019) Eculizumab Safety: five-year experience from the global atypical hemolytic uremic syndrome registry. Kidney Int Rep 4:1568\u20131576. https:\/\/doi.org\/10.1016\/j.ekir.2019.07.016","journal-title":"Kidney Int Rep"},{"key":"13225_CR176","doi-asserted-by":"publisher","first-page":"119","DOI":"10.18553\/jmcp.2022.28.1.119","volume":"28","author":"JA Tice","year":"2022","unstructured":"Tice JA, Touchette DR, Lien PW, Agboola F, Nikitin D, Pearson SD (2022) The effectiveness and value of eculizumab and efgartigimod for generalized myasthenia gravis. J Manag Care Spec Pharm 28:119\u2013124. https:\/\/doi.org\/10.18553\/jmcp.2022.28.1.119","journal-title":"J Manag Care Spec Pharm"},{"key":"13225_CR177","doi-asserted-by":"publisher","first-page":"517","DOI":"10.18553\/jmcp.2024.30.6.517","volume":"30","author":"PW Lien","year":"2024","unstructured":"Lien PW, Joshi M, Tice JA, Agboola F, Nikitin D, Withanawasam V, Jatoi S, Touchette DR (2024) Cost-effectiveness of eculizumab and efgartigimod for the treatment of anti-acetylcholine receptor antibody-positive generalized myasthenia gravis. J Manag Care Spec Pharm 30:517\u2013527. https:\/\/doi.org\/10.18553\/jmcp.2024.30.6.517","journal-title":"J Manag Care Spec Pharm"},{"key":"13225_CR178","doi-asserted-by":"publisher","first-page":"4628","DOI":"10.1007\/s12325-024-03014-5","volume":"41","author":"AG Smith","year":"2024","unstructured":"Smith AG, Wolfe GI, Habib AA, Qi CZ, Yang H, Du M, Chen X, Gelinas D, Brauer E, Phillips G, Sacca F (2024) Risk-Benefit Analysis of Novel Treatments for Patients with Generalized Myasthenia Gravis. Adv Ther 41:4628\u20134647. https:\/\/doi.org\/10.1007\/s12325-024-03014-5","journal-title":"Adv Ther"},{"key":"13225_CR179","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2025.2497906","author":"CA Scheiner","year":"2025","unstructured":"Scheiner CA, Masuda M, Hagenacker T, Powell L, Jayasinghe P, Johnston K, Yee KS (2025) Assessing the symptom control provided by ravulizumab or efgartigimod in myasthenia gravis: an evaluation of the patient experience of two different treatment approaches. Curr Med Res Opin. https:\/\/doi.org\/10.1080\/03007995.2025.2497906","journal-title":"Curr Med Res Opin"},{"key":"13225_CR180","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1007\/s13311-022-01253-4","volume":"19","author":"YA Rajabally","year":"2022","unstructured":"Rajabally YA (2022) Immunoglobulin and monoclonal antibody therapies in guillain-barre syndrome. Neurotherapeutics 19:885\u2013896. https:\/\/doi.org\/10.1007\/s13311-022-01253-4","journal-title":"Neurotherapeutics"},{"key":"13225_CR181","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2023.100290","volume":"3","author":"Y Sun","year":"2023","unstructured":"Sun Y, Wirta D, Murahashi W, Mathur V, Sankaranarayanan S, Taylor LK, Yednock T, Fong DS, Goldberg JL (2023) Safety and Target Engagement of Complement C1q Inhibitor ANX007 in Neurodegenerative Eye Disease: Results from Phase I Studies in Glaucoma. Ophthalmol Sci 3:100290. https:\/\/doi.org\/10.1016\/j.xops.2023.100290","journal-title":"Ophthalmol Sci"},{"key":"13225_CR182","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1182\/blood.2023022153","volume":"143","author":"S D'Sa","year":"2024","unstructured":"D\u2019Sa S, Vos JMI, Barcellini W, Wardecki M, Perrin L, Barker G, Zilberstein M, Storek M, Chow T, Roth A (2024) Safety, tolerability, and activity of the active C1s antibody riliprubart in cold agglutinin disease: a phase 1b study. Blood 143:713\u2013720. https:\/\/doi.org\/10.1182\/blood.2023022153","journal-title":"Blood"},{"key":"13225_CR183","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2410316","author":"V Perkovic","year":"2024","unstructured":"Perkovic V, Barratt J, Rovin B, Kashihara N, Maes B, Zhang H, Trimarchi H, Kollins D, Papachristofi O, Jacinto-Sanders S, Merkel T, Guerard N, Renfurm R, Hach T, Rizk DV (2024) Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2410316","journal-title":"N Engl J Med"},{"key":"13225_CR184","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.1016\/j.ekir.2023.09.017","volume":"8","author":"E Wong","year":"2023","unstructured":"Wong E, Nester C, Cavero T, Karras A, Le Quintrec M, Lightstone L, Eisenberger U, Soler MJ, Kavanagh D, Daina E, Praga M, Medjeral-Thomas NR, Gackler A, Garcia-Carro C, Biondani A, Chaperon F, Kulmatycki K, Milojevic J, Webb NJA, Nidamarthy PK, Junge G, Remuzzi G (2023) Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy. Kidney Int Rep 8:2754\u20132764. https:\/\/doi.org\/10.1016\/j.ekir.2023.09.017","journal-title":"Kidney Int Rep"},{"key":"13225_CR185","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1159\/000527167","volume":"53","author":"C Nester","year":"2022","unstructured":"Nester C, Appel GB, Bomback AS, Bouman KP, Cook HT, Daina E, Dixon BP, Rice K, Najafian N, Hui J, Podos SD, Langman CB, Lightstone L, Parikh SV, Pickering MC, Sperati CJ, Trachtman H, Tumlin J, de Vries AP, Wetzels JFM, Remuzzi G (2022) Clinical Outcomes of Patients with C3G or IC-MPGN Treated with the Factor D Inhibitor Danicopan: final Results from Two Phase 2 Studies. Am J Nephrol 53:687\u2013700. https:\/\/doi.org\/10.1159\/000527167","journal-title":"Am J Nephrol"},{"key":"13225_CR186","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1016\/S0140-6736(23)01520-9","volume":"402","author":"JS Heier","year":"2023","unstructured":"Heier JS, Lad EM, Holz FG, Rosenfeld PJ, Guymer RH, Boyer D, Grossi F, Baumal CR, Korobelnik JF, Slakter JS, Waheed NK, Metlapally R, Pearce I, Steinle N, Francone AA, Hu A, Lally DR, Deschatelets P, Francois C, Bliss C, Staurenghi G, Mones J, Singh RP, Ribeiro R, Wykoff CC, Oak, Investigators DS (2023) Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials. Lancet 402:1434\u20131448. https:\/\/doi.org\/10.1016\/S0140-6736(23)01520-9","journal-title":"Lancet"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13225-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-025-13225-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13225-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T00:25:13Z","timestamp":1757204713000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-025-13225-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,2]]},"references-count":186,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["13225"],"URL":"https:\/\/doi.org\/10.1007\/s00415-025-13225-7","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,2]]},"assertion":[{"value":"11 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The manuscript does not contain clinical studies or patient data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors have no relevant financial or non-financial interests to disclose. The authors have no conflict of interest to declare that are relevant to the content of this article. All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest or non-financial interest in the subject matter or materials discussed in this manuscript. The authors have no financial or proprietary interests in any material discussed in this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"489"}}